Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 16/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817101 | 0.89 | SMN1; SMN2 (0.47) | POLBALDH1A1CYP3A4CYP2C9KMT2A | |
| SCHEMBL1809503 | 0.89 | ADORA1 (0.43) | ADORA1POLBADORA3ADORA2BALDH1A1 | |
| SCHEMBL1818962 | 0.89 | ADORA1 (0.42) | ADORA1POLBTSHRADORA2BALDH1A1 | |
| SCHEMBL1814347 | 0.88 | TAS2R14 (0.45) | ADORA1POLBTSHRADORA2B | |
| SCHEMBL1811983 | 0.87 | ADORA1 (0.44) | ADORA1POLBADORA3ADORA2BKMT2A | |
| SCHEMBL1815547 | 0.85 | KDM4E (0.42) | ADORA1POLBTSHRALDH1A1CYP3A4 | |
| SCHEMBL1817175 | 0.85 | ADORA1 (0.45) | ADORA1ADORA3ADORA2BALDH1A1 | |
| SCHEMBL1810125 | 0.84 | KDM4E (0.42) | ADORA1POLBKMT2A | |
| SCHEMBL1814786 | 0.84 | KDM4E (0.42) | ADORA1ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL1812450 | 0.84 | ADORA1 (0.58) | ADORA1ADORA3ADORA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321296-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | ADORA1 724/4885POLB 2263/4885TSHR 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.